Boron neutron capture therapy for head and neck cancer: Relevance of nuclear-cytoplasmic volume ratio and anti-tumor effect. -A preliminary report-
Boron neutron capture therapy for head and neck cancer: Relevance of nuclear-cytoplasmic volume ratio and anti-tumor effect. -A preliminary report-
复制标题
DOI：
10.1016/j.apradiso.2020.109212
复制
发表时间：
2020-09-01
影响因子：
1.6
通讯作者：
Ono, Koji
中科院分区：
文献类型：
--
作者：
Aihara, Teruhito;Hiratsuka, Junichi;Ono, Koji
BNCT是一种粒子束放射疗法，它利用热中子被选择性地吸收到肿瘤组织中的硼化合物中的10B核俘获时产生的a粒子和7Li核。本报告验证了肿瘤细胞N/C比值与头颈部肿瘤BNCT临床病例抗肿瘤效果的相关性。对9例接受BNCT治疗的头颈部肿瘤患者(CR组4例，非CR组5例)放疗前的肿瘤组织病理标本进行了检查。CR组和非CR组之间的统计学差异被检验，因为物理剂量乘以由患者的肿瘤特异性N/C比率确定的绝对生物学有效性(ABE)值。分析表明，肿瘤的平均剂量不能区分CR组和非CR组。而ABE剂量能明显区分CR组和非CR组(p=0.0250)。肿瘤细胞的N/C比值可影响BNCT对HNC的抗肿瘤作用。
BNCT is a type of particle beam radiation therapy that utilizes an a particle and 7Li nucleus generated when a thermal neutron is captured by a 10B nucleus involved in the boron compound that has been taken up into tumor tissue selectively. In this report, the relevance of N/C ratio of tumor cell and anti-tumor effect for BNCT clinical cases of head and neck cancer were verified. Examination of pre-irradiated tumor histopathological specimens of 9 BNCT treated head and neck cancer patients (4 CR patients, 5 non-CR patients) was performed. The statistically significant difference between the CR group and the non-CR group was examined for the physical dose was multiplied by the absolute biological effectiveness (ABE) value determined from the patient's tumor specific N/C ratio. Analysis showed the mean tumor dose could not distinguish between CR and non-CR groups. However, the ABE dose could clearly distinguish between the CR group and the non-CR group (p = 0.0250). The N/C ratio of tumor cell can influence the anti-tumor effect of BNCT for HNC.